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Background: Fosfomycin is an antibiotic that has seen a revival in use due to its unique mechanism of action
and efficacy against isolates resistant to many other antibiotics. In Escherichia coli, fosfomycin often selects for
loss-of-function mutations within the genes encoding the sugar importers, GlpT and UhpT. There has, however,
not been a genome-wide analysis of the basis for fosfomycin susceptibility reported to date.
Methods: Here we used TraDIS-Xpress, a high-density transposon mutagenesis approach, to assay the role of all
genes in E. coli involved in fosfomycin susceptibility.
Results: The data confirmed known fosfomycin susceptibility mechanisms and identified new ones. The assay
was able to identify domains within proteins of importance and revealed essential genes with roles in fosfomycin
susceptibility based on expression changes. Novel mechanisms of fosfomycin susceptibility that were identified
included those involved in glucose metabolism and phosphonate catabolism (phnC-M), and the phosphate im-
porter, PstSACB. The impact of these genes on fosfomycin susceptibility was validated by measuring the suscep-
tibility of defined inactivation mutants.
Conclusions: This work reveals a wider set of genes that contribute to fosfomycin susceptibility, including core
sugar metabolism genes and two systems involved in phosphate uptake and metabolism previously unrecog-
nized as having a role in fosfomycin susceptibility.
Introduction
The increasing prevalence of bacteria that are resistant to clinically
important antibiotics has led to searches for alternative options to
treat problematic infections.1 There has been limited progress in
the development of new antibiotics and one strategy has been to
revive older drugs that may be effective but are not commonly
used in clinical practice.2 One example is fosfomycin, which has
seen an increase in clinical use in recent years. Fosfomycin has
a unique mode of action where it targets the initial stages of
peptidoglycan biosynthesis by acting as a phosphoenolpyruvate
analogue and inhibiting MurA.3 Consequently, fosfomycin retains
activity against bacterial strains expressing b-lactamases that in-
hibit later peptidoglycan biosynthetic reactions. This is useful given
the prevalence of different b-lactamase enzymes in important
pathogens. Fosfomycin is a phosphonic acid molecule produced in
nature by Streptomyces species and is commonly used for
treatment of complicated urinary tract infections and increasingly
for more serious systemic infections. In Enterobacteriaceae, fosfo-
mycin enters the cell by acting as a mimic for two nutrient importer
systems, GlpT and UhpT.4
Resistance to fosfomycin has been shown to be relatively easy
to select in vitro and resistant mutants often show loss of function
of GlpT or UhpT, or have mutations in adenylcyclase (cyaA) or
phosphotransferase (ptsI) genes, both of which control intracellu-
lar levels of cyclic AMP, which in turn regulates expression of glpT
and uhpT.5–9 In addition, alterations within the drug target MurA
(particularly those altering a Cys115 residue near the active site)
can decrease susceptibility by reducing its affinity for fosfomy-
cin.10–12 Over-expression of murA has also been observed in
fosfomycin-resistant isolates and is thought to act by saturating
the drug.13,14 Resistance to fosfomycin may also be acquired by
genetic transfer of fosA and fosB coding for functions that disrupt
the fosfomycin oxirane ring.15–17
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Whilst it has been easy to select for fosfomycin-resistant
isolates in vitro, there is evidence that selection of resistance
carries a major fitness cost, and that fosfomycin-resistant isolates
may be compromised in virulence.18–20 Various studies have
looked for the prevalence of fosfomycin resistance in different
settings, and resistance rates in general have remained relatively
low, even in high-use settings.21,22
Given the recent increase in the use of fosfomycin, we used a
genome-wide transposon mutagenesis approach in Escherichia
coli to identify loci involved in fosfomycin susceptibility.23 We iden-
tified new loci as being involved in fosfomycin susceptibility, includ-
ing the phosphonate uptake and utilization system and phosphate
import system, as well as identifying sub-domains within some
proteins involved in fosfomycin susceptibility.
Materials and methods
TraDIS-Xpress library
We recently described the construction of a high-density (insert approxi-
mately every 6 bp) TraDIS-Xpress library in E. coli BW25113, which was
used in this work.24 BW25113 is a commonly used reference strain, a full
and well-annotated genome sequence is available, and it was the parent
strain for the KEIO collection of defined insertion mutants, thus enabling
easier validation of the roles of candidate genes.24 The transposon used fa
mini-Tn5 transposon coding for kanamycin resistance [aph(30)-Ia]g incor-
porates an outward-transcribing tac promoter 30 of the kanamycin cassette
that is inducible by IPTG, allowing over-expression or repression of genes
adjacent to insertion sites (depending on insert orientation) as well as gene
inactivation. This allows the roles of essential genes in response to a stress
to be analysed based on expression changes; traditionally these loci have
been cryptic in TraDIS experiments as insertions within them are lethal.
Fosfomycin exposure conditions and TraDIS-Xpress
sequencing
The MIC of fosfomycin for BW25113 was determined using microbroth dilu-
tion in Mueller–Hinton (MH) and LB broth (the same growth medium that
was used for TraDIS-Xpress experiments). For TraDIS-Xpress experiments,
approximately 107 mutants were inoculated into 1.7 mL LB broth in deep
96-well plates containing doubling concentrations of fosfomycin ranging
from 0.25% to 2% MIC (and a drug-free control). Replicate experiments
were completed with no induction, or with the addition of 0.2 or 1 mM IPTG
to induce transcription from the outward-transcribing promoter. Mutants
were grown for 24 h at 37C. All experiments were performed in duplicate
to give a total of 30 independent TraDIS-Xpress experiments (Figure S1,
available as Supplementary data at JACOnline).
After growth under experimental conditions, DNA was extracted from
pools of mutants using a Quick-DNATM Fungal/Bacterial 96 Kit (Zymo
Research). DNA was then fragmented using a Nextera DNA library prepar-
ation kit (Illumina) except that Tnp-i5 oligonucleotides were used instead
of i5 index primers, and 28 PCR cycles. The resulting DNA was sequenced on
a NEXTSeq 500 sequencing machine using a NextSeq 500/550 High Output
v2 kit (75 cycles). All sequence data have been deposited with EBI under
project accession number PRJEB29311.
Bioinformatics
Results were analysed using BioTraDIS (version 1.4.1) and AlbaTraDIS
(version 0.0.5), developed for TraDIS-Xpress analysis and recently
described.25,26 Briefly, BioTraDIS was used to map sequence reads against
the BW25113 reference genome (CP009273) using SMALT and to create in-
sertion plots.
The patterns of inserts were compared between fosfomycin-exposed
and control conditions, AlbaTraDIS then calculated the number of inserts
within each gene as well as assessing the number of forward and reverse
insertions per gene and within a window of 198 bp upstream and down-
stream of each gene. This length for a window was chosen as likely to in-
clude regions within which inserts were likely to influence expression of the
relevant gene. The number of sequence reads was modelled on a per-gene
basis using a negative binomial distribution and an adapted exact test as
implemented in edgeR followed by multiple testing correction to identify
significant differences between conditions (each test condition compared
with insert patterns from drug-free controls).27,28 A set of default cut-offs
for significance and number of reads were applied (q-value 0.05, logFC
1, logCPM >8). This resulted in a list of candidate genes involved in fosfo-
mycin susceptibility as well as a prediction as to whether a change in
expression of a gene (either down- or up-regulated) influences survival. The
insertion patterns at candidate loci were visually inspected using Artemis,
which was also used to capture images for figures.29
Validation experiments
A total of 18 mutants were selected from the KEIO library to validate predic-
tions about susceptibility to fosfomycin made by TraDIS-Xpress.30 These
included genes in the phosphonate uptake and metabolism and phos-
phorus import systems identified as major contributors to fosfomycin sus-
ceptibility as well as a set of randomly selected control genes not expected
to have any impact on fosfomycin susceptibility. Both replicate mutants
present in the KEIO collection (the collection contains two independent in-
sertion mutants for each gene in BW25113) were analysed. Mutants were
tested for their susceptibility to fosfomycin by determination of fosfomycin
MIC. All experiments were duplicated (giving at least four datasets for each
gene: two repeats from each of the two mutant alleles of each gene).
BW25113 was included in all experiments as a control.
The potential for the bis-phosphonate etidronate to antagonize
fosfomycin was evaluated using chequerboard assays where dilutions of
fosfomycin (from 16 to 0.125 mg/L) and dilutions of etidronate (from 400
to 0.4 mg/L) were combined. Plates were incubated for 24 h at 37C in a
FLUOstar Omega plate reader (BMG Labtech) with OD measurements being
taken every 15 min to capture growth kinetics.
Results
Susceptibility of BW25113 to fosfomycin
The MIC of fosfomycin for BW25113 was determined to be 4 mg/L
in both MH and LB broth, and cultures were prepared in LB broth
without or with fosfomycin at 0.25%, 0.5%, 1% and 2% MIC, com-
bined with IPTG at two concentrations to induce transcription from
the outward-transcribing transposon promoter, or without IPTG to
allow promoter repression. Each condition was performed in dupli-
cate to give a total of 30 independent experiments, and each was
inoculated with 107 cfu from the transposon mutant library.
After incubation overnight, DNA was extracted from all cultures,
and transposon insertion sites were identified using TraDIS-Xpress.
Figure S2 shows the concordance between independent repeats
and the impacts of increasing drug concentrations on numbers of
nucleotide sequence reads locating to each gene of the whole
genome.
Genes involved in fosfomycin susceptibility
Whilst exposure to different concentrations of fosfomycin identi-
fied some concentration-dependent genes, 31 were involved in
susceptibility under all fosfomycin conditions (Table 1, Figure S3).
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These included the majority of known, chromosomally encoded
loci that determine fosfomycin susceptibility, with strong signals
identified for murA, the target for fosfomycin, glpT and cyaA. This
validates the specificity of TraDIS-Xpress in identifying genes
involved in fosfomycin susceptibility. The TraDIS-Xpress method
also proved able to assay essential genes. For example, murA is an
essential gene but mutants with inserts that are positioned up-
stream and in the same orientation as murA were highly enriched
in the presence of IPTG (Figure 1). These mutants will over-express
murA, which will help the target saturate the activity of fosfomy-
cin. The high density of the library also allows very high-resolution
analysis; for example, cyaAwas identified as a significant mechan-
ism but enrichment of inserts was restricted to that part of the
gene encoding the regulatory domain (Figure 1). Mutations within
this domain (but not the remainder of the protein) have previously
been reported as being important in determining fosfomycin sus-
ceptibility and TraDIS-Xpress identified that part of the gene
encoding this domain. However, no signal was identified at the
uhpT locus, which has also previously been implicated in
fosfomycin import, although it is not expressed in the test condi-
tions so knockout mutations would have had no selective
advantage.
Identification of new mechanisms that reduce
susceptibility to fosfomycin
As well as loci known to be involved in determining fosfomycin sus-
ceptibility, several new loci were identified by TraDIS-Xpress.
These included the cra, crp, cyaA, galU, glpK, glpX and treC genes,
which are involved in control of available glucose within the cell
(Table 1) and will influence expression of the glucose importers
that are known routes of entry for fosfomycin. Mutants that
over-expressed leuO, a pleiotropic regulator with known roles in
control of stress responses, were strongly selected by fosfomycin
(Figure 1).
Mutants with transposon insertion mutations within the phn
operon coding for phosphonate uptake and degradation were
very strongly selected by fosfomycin (Figure 2). The phosphonate
Table 1. Loci significantly altered in all exposure conditions
Locus Predicted impacts of insertiona Function and interpretation
ahr Over-expression Aldehyde reductase
alsR Inactivation and up-regulation of alsBACEK Allose binding transporter
cmk Inactivated Cytidylate kinase; nucleotide binding
cra Inactivated Catabolite repressor/activator. Global regulator of carbon metabolism
crp Antisense knockdown Global regulator and carbon catabolite repression
cyaA Inactivation of regulatory domain Adenylate cyclase; regulates cyclase activity by carbon source
dacB Intragenic insert at one site Peptidoglycan biosynthesis
galU Inactivated Synthesis of UDP-D-glucose
glpE Inactivation and overexpression of glpD Glycerol metabolism
glpG Inactivated Membrane protein protease
glpK Inactivated Glycerol kinase; key player in glucose control of glycerol metabolism
glpT Inactivated Glycerol uptake; known fosfomycin importer
glpX Protected Fructose bisphosphatase
guaA Inactivation GMP synthesis
ibaG Inactivated, inserts upstream of murA Increase in murA expression
leuA Protected and over-expression of leuO Regulation of stringent response, pleiotropic effects from leuO
leuL Inactivated and over-expression of leuO Pleiotropic effects from leuO
mlaB-F Inactivated, inserts upstream of murA Peptidoglycan recycling; fosfomycin target expression increased
murA Upstream inserts Peptidoglycan biosynthesis; fosfomycin target; expression increased
mutL Protected DNA repair
nagB Inactivated with up-regulation of nagE Over-expression of sugar importer (nagE)
phnC-M Inactivated (all 14 members of operon in sense) Phase-variable phosphonate transporter and degradation complex
phoU Inactivation (downstream of pstB) Repressor of pstABCS phosphate uptake system
pstABCS Inactivated Phosphate uptake system
ptsH Inactivated Decoration of imported sugars with phosphates
purA Inactivated Purine biosynthesis
rfaH Inactivated (inserts antisense to tatD) Transcription anti-terminator
tatD Protected DNA repair
treC Inactivated Hydrolyses trehalose to glucose
waaFGP Inactivated LPS branching
yhfA Protected and up-regulated Conserved hypothetical product, known to be Regulated by CRP
aOver-expression indicates selective advantage for insertions upstream. ‘Protected’ indicates a loss of insertion mutants in the selective condition.
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uptake and degradation operon comprises 14 genes
(phnCDEFGHIJKLMNOP) coding for an ABC importer (PhnCDE), a
regulator (PhnF), a multi-subunit methylphosphonate degradation
complex (PhnGHIJKL), which includes the carbon–phosphorus
bond cleavage activity (PhnGHIJ), and additional functions
required to yield phosphate from phosphonate (PhnMNOP). The
phn operon has been reported to be cryptic in E. coli K12 due to
three, not two, copies of an 8 bp tandem repeat within phnE
(encoding the integral membrane component of the importer)
that cause a frameshift.31 Sequencing of the parent strain of the
transposon library, and mapping of reads obtained from TraDIS
experiments after fosfomycin exposure confirmed that the
Figure 1. Differential selection of transposon mutants at cyaA (a), leuO (b) and murA (c). The bottom of each panel illustrates the genomic context
and the panels above illustrate the mapped reads. Red bars indicate reads orientated left to right and blue bars the opposite. The height of each bar
reflects the abundance of each insert. Data shown are from conditions with IPTG present as an inducer.
Figure 2. Inactivation of the phn (a) and pst (b) operons is selected by fosfomycin. The bottom of each panel illustrates the genomic context and the
panels above illustrate the mapped reads. Red bars indicate reads orientated left to right and blue bars the opposite. The height of each bar reflects
the abundance of each insert.
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BW25113 parent strain, used to make the transposon mutant li-
brary, also has three copies of the tandem repeat within phnE,
which should therefore not be expressed. However, following
growth with fosfomycin at 2% MIC, transposon insertions in the
phnC, phnE and phnF genes conferred a large selective advantage
(Figure 2a). These insertions are all oriented such that the trans-
poson promoter will transcribe the rest of the operon, most likely
leading to its expression, and suggesting that the phosphonate
degradation complex encoded by these genes can modify or de-
grade fosfomycin. At lower concentrations (0.5%MIC) of fosfomy-
cin, insertion mutations in the same orientation were observed
across most of the operon but not within phnMNOP, suggesting
that at this lower concentration these gene products alone provide
sufficient inactivation of fosfomycin to confer a significant select-
ive advantage.
Insertion mutations in the pstSACB operon coding for an ABC
phosphate importer also conferred a selective advantage during
growth with fosfomycin (Figure 2). Insertion mutations in this op-
eron generally showed an antisense orientation bias for at least
two of the genes, which probably reflects the relative selective ad-
vantage or disadvantage of inactivation and altered expression of
the operon components resulting from the different insertions
sites of the transposon and its outward-directed promoter.
In contrast, the DNA repair functions encoded bymutL and tatD
were beneficial for growth with fosfomycin, as insertion mutants
for these genes were lost at all fosfomycin concentrations.
Changes in the expression of some bacterial cell functions
reduce susceptibility to several antibiotics simultaneously. These
functions include efflux transporters, porins and proteins that
regulate their expression directly or indirectly, such as AcrR, MarA
and SoxR.32 The TraDIS-Xpress data indicate that none of these
functions contributes to susceptibility at any of the fosfomycin
concentrations tested, suggesting that selection of cross-
resistance to other antibacterials by fosfomycin is limited.
Validation of targets
To test the predictions made by TraDIS-Xpresswe tested nine pairs
of insertion mutants from the KEIO collection for susceptibility to
fosfomycin by growth on LB agar containing different
concentrations of the drug (Figure 3). As expected, BW25113 was
inhibited by the MIC. Growth of both the leuO mutants was also
inhibited at the MIC, and this is also expected as the TraDIS-Xpress
data predicted that altered leuO expression, rather than inactiva-
tion, was important for reduced fosfomycin susceptibility. For all
the other mutant pairs, one or both showed a 2- to 4-fold increase
in MIC of fosfomycin compared with the BW25113 parent strain.
These mutant pairs included three for the phn operon and both
the pst mutants tested (Figure 3). Given the indicated role for the
phosphonate uptake system, we tested whether addition of an ex-
ogenous phosphonate would impact fosfomycin susceptibility and
found that 100 mg/L of the bis-phosphonate etidronate increased
the MIC of fosfomycin against BW25113 by 2- to 4-fold. In add-
ition, growth curve experiments indicated that the addition of
100 mg/L etidronate resulted in improvements in growth rate of
BW25113 cultures supplemented with different concentrations of
fosfomycin (Figure S3). Etidronate alone showed no antibacterial
activity (Figure S3).
Discussion
The mechanisms of fosfomycin action and resistance known to
date have largely been elucidated by the study of individual
mutants and isolates that demonstrate fosfomycin resistance.18
Here, we used TraDIS-Xpress to assay the role of the whole gen-
ome of E. coli in fosfomycin susceptibility in a series of parallel
experiments. The data showed the sensitivity of this approach,
with many of the known chromosomal mechanisms of resistance
being identified as important contributors to fosfomycin suscepti-
bility (apart from uhpT, which is not expressed in the assay condi-
tions used). Additionally, TraDIS-Xpress was also able to identify
domains within targets that are important; for example, the
regulatory domain of CyaA is known to be involved in fosfomycin
susceptibility by controlling cAMP levels and therefore expression
of glpT and uhpT.19 Inactivation of the CyaA domain responsible
for this function results in lower expression of both GlpT and UhpT
importers, and reduced fosfomycin susceptibility. TraDIS-Xpress
clearly indicated the role for this regulatory domain but not the
rest of cyaA (Figure 1). In line with the identification of cyaA as im-
portant, our data also identified inactivation of glpT as providing a
Figure 3. Validation of specific mutants by inoculation onto agar containing different fosfomycin concentrations. Panels (a) and (b) represent ana-
lysis of both independent mutants for each gene present in the KEIO collection. For each strain, 5lL spots representing 104 cfu were inoculated
and incubated overnight at 37C. Concentrations are indicated as fractions of the MIC (4 mg/L) for BW25113.
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selective advantage with fosfomycin as expected, although there
was no signal for uhpT.
Traditional TraDIS experiments have not been able to assay
many essential genes, which often reduce susceptibility to antibi-
otics. However, the current work demonstrates that TraDIS-Xpress
did assay essential genes following growth in fosfomycin, as
exemplified by the selection of many mutants with transposon
insertions upstream ofmurA and oriented to promote transcription
from the outward-transcribing transposon promoter. These inser-
tions most likely increase expression, increasing the number of
copies of MurA beyond that which can be inhibited by fosfomycin.
In addition to genes known to be involved in fosfomycin resist-
ance, a wider set of new loci were also identified as contributing to
susceptibility to the drug (Table 1). These included genes involved
in glucose metabolism, which are likely to mediate expression of
the glucose importers that facilitate transport of fosfomycin across
the inner membrane. This extends our current understanding of
how central metabolism can impact susceptibility to fosfomycin
and shows how specific growth conditions and associated gene
expression may influence susceptibility to this drug by altering
gene regulation.
These experiments also found that knockout mutations in
mutL and tatD were selectively disadvantageous for growth in
fosfomycin. These genes encode DNA repair functions, suggesting
that fosfomycin causes some DNA damage resulting from altered
metabolism following inhibition of the primary target, MurA, and
consequent bactericidal effect. This has been proposed as a com-
mon impact of many bactericidal drugs.33–35
The TraDIS-Xpress data indicated that transposon insertions
into the phosphonate uptake and catabolism operon
(phnCDEFGHILJLMNO) provided a considerable selective advan-
tage for growth in fosfomycin. All these insertions were oriented
such that the transposon outward-transcribing promoter would
promote expression of downstream genes, suggesting that the
products of this system can inactivate fosfomycin. At 0.5%MIC fos-
fomycin, insertions were found across most of the operon, but not
within phnMNOP, suggesting that at lower fosfomycin concentra-
tions one or more of these functions is sufficient for fosfomycin in-
activation. At the highest fosfomycin concentration investigated,
insertions were upstream of phnG, and orientated towards phnG-
P, thereby over-expressing the lyase components. The lack of
transposon insertions in the reverse orientation within phnCDE
indicates the selective advantage is not likely to be due to inactiva-
tion of transport, which should remain inactive throughout the
experiment due to the phnE frameshift mutation. There was,
however, a phenotype for the phnC mutant, and phnCD will be
Figure 4. Summary of pathways implicated in fosfomycin entry into the cell. Proposed model of roles for genes identified as being involved in fosfo-
mycin susceptibility. Fosfomycin is indicated by red circles and known and potentially novel mechanisms of uptake are indicated by solid and dashed
green arrows, respectively.
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expressed as they are upstream of the frameshift even though
phnE is inactive. Therefore, these results indicate that it is most
likely expression of the phosphonate metabolism system,
phnGHIJKLMNOP, that provides a selective advantage during
growth with fosfomycin.
Whilst UhpT and GlpT are known import systems for fosfomy-
cin, mutation of either the PhnC-M or PstBCSA system was strongly
selected by fosfomycin exposure (Figure 2).
The PstBCAS phosphate transporter was also identified as a like-
ly mechanism of fosfomycin entry into the cell, as insertion muta-
tions into the pstBCAS operon conferred a selective advantage
during growth with fosfomycin (Figure 2). These data suggest that
multiple importers, including novel systems, are involved in fosfo-
mycin susceptibility. Testing of defined mutants in both the Phn
and Pst systems confirmed a phenotype, with the mutants able to
grow above the MIC of the drug (Figure 3).
In addition, growth in the presence of the bis-phosphonate
etidronate resulted in limited but consistent (2-fold increase in the
MIC) rescue of growth in the presence of fosfomycin. Figure S4
shows the impact of addition of 100 mg/L of etidronate on growth
in the presence of a series of concentrations of fosfomycin, with
improved growth evident at most concentrations (etidronate had
no intrinsic antimicrobial activity). These data are supportive of
specific phosphonate importers being important routes of entry
into the cell for fosfomycin. The potential for phosphonate moi-
eties to mediate import of molecules into the cell may have poten-
tial utility. A major challenge in therapy is getting drugs into cells
and new routes to modify molecules and promote their uptake are
likely to enhance efficacy of drugs. It has become clear in recent
years that most drugs cross the inner membrane by active import
rather than passive diffusion and identifying side groups that may
improve uptake by changing importer specificity is important.36
One major worry with some drugs is selection of cross-
resistance to other agents, often mediated by generic mecha-
nisms of resistance, including multidrug efflux and/or porins,
where expression changes can influence accumulation of many
drugs.32 There was not a strong signal for these pathways after
fosfomycin exposure, which suggests that the major mechanisms
of fosfomycin resistance (we propose a model in Figure 4) are likely
to be relatively specific and not influence other classes of agent.
This is potentially important as, whilst fosfomycin resistance is not
hard to select, a key feature of this drug is its activity against strains
resistant to other drugs, in particular various b-lactams.
Taken together, these data show a genome-wide analysis
of genes not known previously to be involved in susceptibility to
fosfomycin. These include a role for Pst as a transporter and
the phosphonate catabolism pathway as a putative inactivator of
fosfomycin.
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